<DOC>
	<DOCNO>NCT00003328</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether radiation therapy follow porfiromycin effective radiation therapy alone treat patient head neck cancer . PURPOSE : Randomized double-blinded phase III trial determine effectiveness radiation therapy follow porfiromycin treating patient stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Radiation Therapy Plus Porfiromycin Treating Patients With Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine time tumor progression patient stage III IV ( without distant metastasis ) head neck cancer treat porfiromycin adjuvant therapy radiotherapy . II . Determine percentage patient locoregional tumor recurrence 2 year posttreatment . III . Determine response rate , disease free survival time , overall survival time patient . IV . Evaluate safety tolerance porfiromycin patient . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord primary tumor site ( oral v pharynx v larynx ) disease stage ( T N stage : T1-2 v T3-4 N0 v N1-2 v N3 ) . All patient randomize receive either porfiromycin ( arm I ) placebo ( arm II ) adjuvant therapy radiation therapy . Both arm follow treatment schedule . Daily radiation therapy commences day 1 . Patients receive porfiromycin placebo intravenous infusion 30-60 minute day 5 day 46 47 . Porfiromycin placebo administer 30 minute 2 hour follow radiation therapy . All patient N3 neck disease ( metastases lymph node 6 cm great dimension ) undergo plan neck dissection follow external beam radiation 4 12 week follow therapy . This surgery need patient N3 neck disease residual disease follow radiotherapy . Patients follow 4 week , every 2 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 550-600 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Porfiromycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV squamous cell ( epidermoid ) carcinoma head neck limit oral cavity , oropharynx , hypopharynx , larynx No distant metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 75,000/mm3 No know bleed disorder Hepatic : Bilirubin great 2 time normal No end stage liver disease PT PTT great 1.5 time normal Renal : Creatinine le 2 time normal No end stage renal disease Cardiovascular : No unstable angina Pulmonary : No severe oxygen dependent chronic obstructive pulmonary disease Other : No malignancy know active within past 5 year except basal squamous cell skin cancer outside plan radiation portal carcinoma situ cervix No life threaten illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy head neck cancer Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy head neck cancer Surgery : No prior surgery ( biopsy ) head neck cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
</DOC>